To test whether fosinopril is more effective than HCTZ in slowing carotid atherosclerosis progression, in comparison to placebo, is pravastatin more effective when added to treatment, and if additive effects occur between ACE inhibition and lipid-lowering therapies. Here, ACE is linked to carotid atherosclerosis.